they have around $4 a share in cash, a very promising migraine drug in stage 3, and AZN has not pulled out of their deal with mapp to commercialize their asthma drug. MAPP will go back to $7 when weak hands get done panicking.
Why would Astra stick around? They fail the trial, the FDA isn't going to approve it. They could do another trial, somebody mentioned that, but that's a lot of money, and doesn't the FDA have to approve another trial? I'm not in that business so someone enlighten me. But I am in the investment business and if my investment was going to hell, I wouldn't stick around. Companies like Astra can take risks and the say whoops, made a mistake, so long. You sound like you're an employee that doesn't want to give up on the ship. I just want to get back to even on this mess. But I don't think its weka hands, man, I think its facing the facts.